ArticleJournal of managed care & specialty pharmacy2025
Halting hyaluronidase hopping to maintain the integrity of Medicare drug price negotiation.
Article in Journal of managed care & specialty pharmacy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Inflation Reduction Act empowered Medicare to negotiate drug prices for certain drugs, but the initial program guidance treated fixed-dose combination drugs separately, which would allow manufacturers of biologics to launch subcutaneous versions coformulated with hyaluronidase to defer negotiation eligibility, which we call "hyaluronidase hopping." In May 2025, the Centers for Medicare & Medicaid Services issued draft guidance requesting comments on a policy that could partially address hyaluronidase hopping by selecting and negotiating fixed-dosed combination products that contain therapeutically inactive ingredients (eg, hyaluronidase) alongside the original noncombination product. This proposed change was not adopted in the final guidance released in September 2025, although it will still be under consideration in future years. Adopting the proposed change is one of several policies needed to safeguard negotiation from hyaluronidase hopping to protect savings and patient access.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.